Market Analysis and Insights: Global Antibody Drug Conjugate Market
The global Antibody Drug Conjugate market was valued at US$ 1831.1 in 2020 and will reach US$ 2796.7 million by the end of 2027, growing at a CAGR of 7.3% during 2022-2027.

Global Antibody Drug Conjugate Scope and Market Size
The global Antibody Drug Conjugate market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Adcetris
Kadcyl
Other

Segment by Application
Hospital
Pharmaceutical Company
Research Institutions

The Antibody Drug Conjugate market is analysed and market size information is provided by regions (countries). Segment by Application, the Antibody Drug Conjugate market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited